Acylation stimulating protein (ASP) acute effects on postprandial lipemia and food intake in rodents. by Saleh, J et al.
UC Davis
UC Davis Previously Published Works
Title
Acylation stimulating protein (ASP) acute effects on postprandial lipemia and food intake in 
rodents.
Permalink
https://escholarship.org/uc/item/9dk8z8jp
Journal
International journal of obesity and related metabolic disorders : journal of the International 
Association for the Study of Obesity, 25(5)
ISSN
0307-0565
Authors
Saleh, J
Blevins, JE
Havel, PJ
et al.
Publication Date
2001-05-01
DOI
10.1038/sj.ijo.0801613
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
PAPER
Acylation stimulating protein (ASP) acute effects on
postprandial lipemia and food intake in rodents
J Saleh1, JE Blevins2, PJ Havel3, JA Barrett2, DW Gietzen2 and K Cianflone1*
1Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Quebec,
Canada; 2School of Veterinary Medicine, Department of Anatomy, Physiology and Cell Biology and the Food Intake Laboratory,
University of California, Davis, CA, USA; and 3Department of Nutrition, University of California, Davis, CA, USA
BACKGROUND: In vitro studies have shown that acylation stimulating protein (ASP) stimulates triglyceride (TG) synthesis and
storage in adipocytes. We have previously demonstrated that intraperitoneal (i.p.) injection of ASP in C57BL=6J mice accelerated
TG clearance following an orally-administered fat load as well as reducing postprandial glucose levels.
RESULTS: In the present study, we first examined the effect of i.p. and intracerebroventricular (i.c.v.) injection of ASP on food
intake in Sprague – Dawley rats. Intraperitoneal injection resulted in a short-term increase in food intake (maximum increase
29.3% within the first hour, P<0.025) decreasing thereafter as compared to vehicle alone. i.c.v. Administration of a comparable
dose of ASP resulted in a similar but delayed increase in food intake with a maximum at 2 – 4 h, suggesting that the actions of ASP
are peripherally mediated. However, there was no significant difference in 24 h food intake with either i.p. or i.c.v. injection. We
also examined the effects of ASP on TG clearance in two obese mouse strains with different metabolic profiles: ob=ob (C57BL=6J-
Lepob) and db=db (C57BLKS=J-Leprdb). In a crossover design, the response to an oral fat load was determined with and without
i.p. injection of exogenous ASP. In ob=ob mice, there was a 44% greater clearance of postprandial TG (area under the curve
(AUC)24549 control vs 138 43 mg=dl h with ASP; P< 0.05 by RM ANOVA). The db=db mice showed a greater response,
with a 62% decrease in postprandial TG (AUC 40801489 control vs 1540719 mg=dl h with ASP; P0.004 by RM ANOVA).
In addition there were decreases in postprandial glucose and non-esterified fatty acid (NEFA) levels in response to ASP.
CONCLUSION: These results are the first to report that ASP can increase food intake in rats and also enhance postprandial TG
clearance in obese animals. These data therefore support previous in vitro evidence pointing to ASP as a regulator of lipid
metabolism.
International Journal of Obesity (2001) 25, 705 – 713
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Introduction
There are many factors which regulate food intake, including
glucocorticoids, growth hormone, catecholamines, numer-
ous gastrointestinal factors and others.1 – 3 Relatively few of
these have been shown to have a direct effect on nutrient
partitioning of ingested food in tissues, in particular trigly-
ceride (TG) storage in adipose tissue.4 Insulin and leptin are
examples of two such metabolic hormones that have
received wide attention for their roles in these processes.
Insulin is a potent metabolic hormone, which increases
glucose transport, decreases hormone sensitive lipase activity
and increases fatty acid incorporation into adipose tissue.4
Insulin is transported into the central nervous system where
it acts as a long-term regulator of energy balance and adip-
osity via its central actions to inhibit food intake.5 – 7 Animals
with genetically induced deficits in insulin signalling in the
central nervous system exhibit increased food intake and
adiposity.8 Circulating insulin concentrations increase in
response to dietary influxes of glucose and protein.3,9 Circu-
lating insulin concentrations are often increased in obesity
as a consequence of insulin resistance.
Leptin is an adipocyte-derived hormone whose circulating
levels closely relate to adipose tissue mass and recent energy
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intake.10 Leptin is most well known for its central actions in
the brain where, like insulin, it acts potently to inhibit food
intake and increase energy expenditure. However, leptin also
has direct peripheral actions on adipose tissue to increase
lipolysis,11,12 oxidation,13 and inhibit insulin mediated sti-
mulation of glucose transport, lipogenesis, fatty acid
synthase expression and insulin binding,13 – 17 although not
all studies have reported such effects.18 – 20
Acylation stimulating protein (ASP) is a recently described
metabolic factor, which like insulin and leptin has metabolic
effects on adipocytes. Like leptin, ASP is produced by adipo-
cytes and like insulin, ASP demonstrates anabolic effects on
glucose and fat storage.review21 ASP is produced through the
interaction of complement C3, factor B and adipsin, all three
of which are produced by adipocytes. C3, the precursor to
ASP, binds factor B, generating an active site for the enzy-
matic action of adipsin, which ultimately produces C3a.
Carboxypeptidase removes the carboxyl terminal arginine
of C3a to generate ASP (C3adesArg).
Evidence suggests that there is a specific saturable receptor
for ASP, which is highly expressed in adipocytes.22 Interac-
tion of ASP with adipocytes generates a metabolic cascade
similar to that of insulin: ASP increases glucose transport,
increases fatty acid incorporation into adipose tissue and
inhibits hormone sensitive lipase.21,23 However the signal
transduction pathway of ASP would appear to be different
from insulin, although the effects are additive to those of
insulin.21,23 – 25 As with insulin and leptin, circulating ASP
increases in obesity.26 Within the adipose tissue bed (as
determined by arterial – venous adipose tissue gradient stu-
dies) there is an increased production of ASP postprandially
with a maximum at 3 – 5 h; however the levels in the general
circulation demonstrate little change.9,27 This is later than
the peak circulating insulin, but occurs at a time when LPL
mediated TG hydrolysis is maximal and is consistent with
the in vitro effect of chylomicrons on ASP production in
human adipocytes.28,29
Acute in vivo intraperitoneal (i.p.) ASP administration in
C57BL=6J mice demonstrated that ASP accelerated postpran-
dial TG and non-esterified fatty acid (NEFA) clearance fol-
lowing a fat load.30 ASP also had an effect on plasma glucose,
enhancing the return to basal levels over the 6 h time course.
On the other hand, C3 knockout mice (which are ASP
deficient) demonstrated delayed TG clearance following a
fat load,31,32 although this was not confirmed elsewhere.33
The mice also have moderate reductions in adipose tissue
mass,32,34 but normal fat absorption,34 consistent with
the proposed role of ASP in enhancing dietary storage
mechanisms.32
The aim of the present study was to further examine the
acute effects of ASP. Since both leptin and insulin have
central effects on feeding behaviour, in addition to their
peripheral actions on adipocyte metabolism, we wondered
whether ASP might also exert an effect on food intake. It has
been demonstrated that adipsin, factor B and C3 are synthe-
sized in brain cells (astrocytes),35 C3adesArg (ASP) is present
in cerebrospinal fluid at concentrations approximately 15
times lower than plasma,36 and intra-cerebroventricular
(i.c.v.) injection of C3a increased the feeding response to
norepinephrine in rats.37 We first examined the effects of i.p.
and i.c.v. injections of ASP on food intake in rats. Second, we
also examined the acute postprandial response to ASP in two
obese mice models, ob=ob (C57BL=6J-Lepob) and db=db
(C57BLKS=J-Leprob), which both present with insulin
abnormalities and non-functional leptin pathways. A fat
load was used, rather than a mixed meal, in order to mini-
mize insulin changes and examine only the effects of ASP.
Methods
Surgical implantation of i.c.v. cannulas in rats
Adult, male Sprague – Dawley rats (220 – 250 g) were obtained
from Simonsen Laboratories (Gilroy, CA). Animal care was
according to the National Institutes of Health guidelines and
the animal protocols were approved by the University of
California, Davis Animal Use and Care Committee. Rats were
surgically implanted with cannulas directed towards the
lateral ventricle as previously described.38 In brief, animals
were anaesthetized with a ketamine cocktail as described
previously39 and placed in a stereotoxic apparatus. Unilateral
stainless steel guide cannulas were inserted using the coor-
dinates of Paxinos and Watson40 and fastened to the skull
with dental acrylic. Penicillin (60 000 units i.m.) was admi-
nistered at the completion of surgery. Following implanta-
tion, rats were fed a moistened 20% casein protein diet for at
least 8 days prior to the i.c.v. injections. During this time,
they were adapted to handling and to a 1 h period of fasting
prior to the onset of the dark cycle. To verify cannula
placement, angiotensin II was administered 3 – 4 days prior
to (100 ng=5 ml) and 3 – 4 days following (100 ng=15 ml) the
test (control and ASP) injections.41 Results from animals not
drinking greater than 5 ml during the 30 min angiotensin II
test were excluded from further analysis. At the completion
of the experiments, the animals were sacrificed, the brain
fixed and sectioned. Animals with injection sites outside the
lateral ventricle were excluded from the analysis.
i.c.v. and i.p. injections and food intake in rats
To determine baseline food intake, food bowls were weighed
(0.1 g) during two consecutive days prior to the i.c.v.
injections. For the i.c.v. injection experiments, each animal
received injections of 15 ml of aCSF (artificial cerebrospinal
fluid) or ASP (5 or 25 mg in 15 ml of aCSF) in random order.
Injections were made by lowering the 33 gauge injector,
connected to a microinjection pump (CMA=100, Bioanaly-
tical Systems, West LaFayette, IN) into the lateral ventricle.
The infusion rate was 3.75 ml=min over 4 min administered
90 min prior to the start of the dark cycle. The injection
needle was left in place for 60 s before being removed. There
was a 2 – 3 day washout period between each injection of
ASP. For i.p. administration, animals were given an injection
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of 48 mg ASP=kg body weight or saline (1 ml=g body weight,
average body weight 313 g). Using a crossover design, rats
were injected i.p. with ASP or vehicle 30 – 90 min prior to the
initiation of the dark cycle, food intake was measured over
specific time intervals and the cumulative food intake calcu-
lated. Differences (with vs without ASP) were calculated for
each animal for each time interval. The same group of
animals was used for i.c.v. and i.p. injections.
Baseline characterization of mice
ob=ob (C57BL=6J-Lepob) and db=db (C57BLKS=J-Leprdb) male
and female mice were obtained from Jackson Laboratories,
Bar Harbour, Maine. In the studies performed, no difference
was seen in male vs female mice, and the data are presented
as pooled data. The mice were weighed and a fasting blood
sample (150 ml) was obtained by tail bleeding. Plasma NEFA
and TG were measured using colorimetric enzymatic kits
(Boehringer Mannheim, Laval, Quebec, Canada). Fasting
insulin was measured using a rat insulin RIA kit with rat
insulin standards which crossreact with mouse insulin as
indicated by the supplier (Linco Research Inc., St Charles,
MO). Fasting plasma glucose was measured using a Trinder
glucose kit (Sigma, St Louis, MO). All animal studies were
approved by the Animal Care Committee at the Royal
Victoria Hospital=McGill University and were in accordance
with standard procedures.
Postprandial fat load on mice
An oral fat load was administered by intragastric feeding to
ob=ob and db=db mice (male and female), 11 – 14 weeks old,
as described previously30 – 32 according to published meth-
ods.42 – 44 Following an overnight fast, 400 ml of olive oil
(followed by 100 ml air) were given based on 10 ml=g mouse
weight.42 – 44 Half the mice received an i.p. injection of
human ASP (500 mg) in phosphate buffered saline (PBS, pH
7.4) containing 1 mg=ml bovine serum albumin (BSA) in a
maximum volume of 300 ml (the other half were sham
injected with placebo — buffer solution containing BSA but
no ASP). Two weeks later the procedure was repeated with
the other half of the mice receiving human ASP. Human ASP
is very similar to mouse ASP45 and has been shown to have
equal bioactivity on human and mouse cells in vitro.46 Blood
samples (40 ml) were collected by tail bleeding at 0, 1, 2, 3, 4
and 6 h into EDTA-containing tubes and centrifuged. Plasma
isolated was used to measure TG, NEFA, glucose (as above)
and plasma human ASP.
ASP purification and quantitation
Human plasma ASP was prepared as previously described in
detail.47 Following the last step of purification on an HPLC
Vydac C4 column (1.025 cm, Separation Group, Hesperia,
CA), the fractions containing ASP were pooled and aliquoted
in siliconized microtubes (Diamed, Mississauga, Ontario,
Canada) and the solvent was evaporated in a vacuum cen-
trifuge. Stock solutions of fatty acid free BSA (10 mg=ml) and
10 stock of PBS were added to the vials prior to evaporation
of the solvent and the ASP=BSA=PBS was reconstituted in
sterile water to yield a final concentration of ASP from 0.5 –
1.0 mg=ml in 1 mg=ml BSA in PBS and stored at 780C. For
i.c.v. injections, ASP was reconstituted in aCSF solution.
Repeated freezing and thawing was avoided since this inac-
tivates ASP. As well, it is essential to store ASP in siliconized
tubes since it sticks easily to glass and plastic, a common
feature of small basic proteins. The concentration of human
ASP in mouse plasma was determined by a polyclonal-mono-
clonal sandwich enzyme linked immunosorbent assay
(ELISA) specific for human ASP.9
Statistics
Results are expressed as average standard error of the mean
(s.e.m.). Results of the curves are compared by two-way
repeated measures ANOVA (RM ANOVA) with Bonferroni
post-test to examine the differences at each time point. As
well, the area under the postprandial curve (AUC) was
determined using a linear trapezoidal equation (Sigma Stat,
Jandel Scientific, San Rafael, CA) and results with vs without
ASP administration were compared by paired t-test, where
NSnot significant.
Results
Effect of acute ASP on food intake in rodents
The results for i.p. injection of ASP are shown in Figure 1.
Following ASP injection, there was an acute increase (average
peak increase29.3%, P<0.025) in cumulative food intake
after 1 h of feeding which decreased gradually thereafter (no
Figure 1 Effect of i.p. administration of ASP on cumulative food intake
in rats. ASP (15 mg) or vehicle was injected i.p. prior to initiation of the
dark cycle (time 0). Cumulative food intake was then measured at the
indicated times. Results are presented as the difference in food intake for
ASP vs vehicle alone as average s.e.m. for n15 rats, where *P<0.05
and **P<0.025.
ASP in ob=ob and db=db mice
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overall difference by 4 h). To determine if this was due
primarily to a peripheral vs central effect, ASP was also
administered i.c.v. Food intake in rats was measured follow-
ing i.c.v. injection of vehicle and 5mg ASP given in random
order. The results are shown in Figure 2. Although the
magnitude of the effect obtained by i.c.v. administration
was comparable to the i.p. ASP effect (maximum 36.7%, P
NS vs i.p.), the time that it took to increase food intake and
i.c.v., administration was considerably longer (2 – 4 h post
dark cycle initiation for i.c.v. injection vs 0.5 – 1 h i.p. for
maximal effect), suggesting that the effect of ASP to increase
food intake is mediated primarily through a peripheral
mechanism. Increased i.c.v. dose (25 mg) tested on a subset
(n9) of rats (given in random order) did not produce any
additional effect (maximum 22.4% P NS for i.c.v. 25 vs i.c.v. 5
by two-way RM ANOVA).
Effect of acute i.p. ASP on postprandial lipemia in obese
ob=ob (C57BL=6J-Lepob) and db=db (C57BLKS=J-Leprdb)
Basal plasma lipids (TG, cholesterol and NEFA), glucose and
insulin concentrations of both ob=ob and db=db mice are
shown in Table 1. Compared to C57BL=6J (B6 control) mice,
the db=db mice were hypertriglyceridaemic and hyperglycae-
mic while plasma total cholesterol and insulin levels were
similar to B6 controls. Ob=ob mice on the other hand had
higher glucose, total cholesterol, HDL-cholesterol and insu-
lin compared to B6 controls.30,48,49 Figure 3, left panel, shows
the plasma postprandial increase in TG from 0 to 6 h follow-
ing the fat load in the ob=ob mice. Postprandial TG levels
increased significantly above basal by 1 h postprandially
(P<0.001 vs fasting TG) reaching two-fold over baseline at
2 h (10617 mg=dl, P<0.01 vs fasting TG). Plasma TG gra-
dually returned towards fasting levels, although they were
still above baseline at the end of the 6 h postprandial period.
Figure 2 Effect of i.c.v. administration of ASP on cumulative food intake
in rats. ASP (5 or 25 mg) or vehicle was injected i.c.v. prior to initiation of
the dark cycle (time 0). Cumulative food intake was then measured at the
indicated times. Results are presented as the difference in food intake for
ASP vs vehicle alone as average s.e.m. for n13 (5 mg dose) and n9
(25 mg dose) rats, where *P<0.025.
Table 1 Plasma parameters in ob=ob (C57BL=6J-Lepob) and db=db
(C57BLKS=J-Leprdb) obese mice
ob=ob db=db B6 controla
Plasma parameters (n8) (n 9) (n 12)
Weight (g) 51.51.0 41.2 1.5 23 – 25
Triglycerides (mg=dl) 44.41.7 93 5.9a 34.8 2.1
Glucose (mg=dl) 19027.7a 471 34.6a 111 4
Total cholesterol (mg=dl) 203.36.9 128 5.3 ND
HDL cholesterol (mg=dl) 165.35.3 104.3 6.3 ND
LDL cholesterol (mg=dl) 37.972.6 23.7 4.2 ND
NEFA (mM) 0.470.05 0.66 0.07 0.41 0.04
Insulin (ng=ml) 1.490.19 0.46 0.05 ND
Fasting plasma parameters as well as body weight are given for B6 control,
ob=ob and db=db as average s.e.m. where NDnot determined. Groups
are compared by ANOVA where *P< 0.05 vs B6 control mice.
aAs published previously.30
Figure 3 Postprandial TG and NEFA in ob=ob (C57BL=6J-Lepob) mice. A fat load was administered at time zero with or without i.p. injection of ASP (as
indicated). Plasma triglycerides (TG) (left panel) and non-esterified fatty acids (NEFA) (right panel) were measured serially. Results are presented as
average s.e.m. for eight mice. Results were analyzed by RM ANOVA with Bonferroni post-hoc test for differences at specific time points with vs without
ASP where: TG, P<0.0001 time, P<0.05 group; NEFA, P NS time, P<0.02 group and *P<0.05 for individual time points with vs without ASP.
ASP in ob=ob and db=db mice
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With ASP injection (given at time 0), a decrease in circulating
TG levels was seen, especially at the first hour postprandially
(P<0.05 vs non-ASP control by RM ANOVA). Overall there
was a 44% decrease in AUC in the presence of ASP, a decrease
which is comparable to the B6 control mice.30 Figure 3, right
panel, shows the changes in NEFA levels in ob=ob over the
same postprandial period in mice. A significant increase in
NEFA was seen 2 h postprandially and the overall profile was
similar to that seen in B6 control mice.30 Generally, there
was a trend towards lower plasma NEFA following ASP
injection compared to ob=ob control (P<0.02 by RM
ANOVA).
Following the fat load, TG levels increased significantly in
db=db mice (Figure 4, left panel) with a 10-fold increase over
basal by 3 h (P<0.02 vs fasting TG). Very high TG levels
persisted over the whole postprandial period and at 6 h were
still 10-fold above basal (P<0.001 vs fasting TG). i.p. injec-
tion of ASP produced a much more profound effect in the
db=db mice compared to the ob=ob mice. There was a sub-
stantial decrease in plasma TG levels over the time course of
the postprandial period (P0.004 by RM ANOVA, P<0.05 at
2, 3, 4 and 6 h vs non-ASP control). Moreover, the AUC was
reduced by 62% with ASP. In the mice injected with exogen-
ous ASP, the TG levels were close to baseline levels by 6 h
postprandially. Figure 4, right panel, shows the postprandial
changes in NEFA in the db=db mice. There was a significant
increase in NEFA by 2 h after the fat load in the control mice
(P<0.01 vs fasting NEFA). This increase was sustained over
the course of the postprandial period (as with TG). Injection
of ASP resulted in small but not significant change in NEFA.
Plasma levels of exogenous ASP
Following i.p. administration of ASP, a marked surge of
exogenous human ASP was seen in the plasma of both
ob=ob and db=db mice during the first hour (Figure 5). The
levels remained elevated and then gradually decreased over
the time course of the fat load and were cleared from the
plasma by 6 h postprandially. Thus bioactive ASP was present
at comparable levels in both ob=ob and db=db mice, although
the effects on TG clearance appeared to be more pronounced
in the db=db (Figures 3 and 4).
Effect of ASP on postprandial glucose levels in both ob=ob
and db=db mouse models
By one hour postprandially, glucose levels increased maxi-
mally in both ob=ob and db=db mouse models (32932 and
110869 mg=dl, respectively, Figure 6). Ob=ob mice had a
65% increase in glucose by 1 h and the levels returned to
baseline by 3 h (Figure 6, top panel). ASP consistently
reduced the glucose level (741% AUC, P0.009 by RM
ANOVA with vs without ASP). Fasting glucose levels were
substantially higher in db=db mice (Table 1). The increase at
1 h was much greater (P<0.0001 vs fasting glucose) and had
not returned to baseline levels by the end of the postprandial
period (Figure 6). Exogenous ASP induced a decrease com-
pared to control levels only at 4 h (P<0.05 vs non-ASP
control) and 6 h (P<0.01 vs non-ASP control) in the db=db
mice (Figure 6, bottom panel). Thus the return to fasting
glucose levels was delayed in the db=db mice as compared to
ob=ob mice and B6 control mice,30 where the drop occurred
earlier (by 1 h) and was sustained over the whole postprandial
period.
Discussion
In the present study, we have demonstrated that i.p. admin-
istration of ASP has effects on energy intake by increasing
short-term acute feeding in rats and enhancing dietary TG
Figure 4 Postprandial TG and NEFA in db=db (C57BLKS=J-Leprdb) mice. A fat load was administered at time zero with or without i.p. injection of ASP (as
indicated). Plasma triglycerides (TG) (left panel) and non-esterified fatty acids (NEFA) (right panel) were measured serially. Results are presented as
average s.e.m. for nine mice. Results were analysed by RM ANOVA with Bonferroni post-hoc test for differences at specific time points with vs without
ASP where: TG, P<0.005 time, P0.004 group; NEFA, P<0.05 time, P NS group and *P<0.05, **P<0.025 for individual time points with vs without
ASP.
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and glucose disappearance after an oral fat load in two obese
mouse models: ob=ob which are obese but normotriglyceri-
demic and db=db which are both obese and diabetic. This
study both extends and complements our previous studies
which demonstrated an effect of ASP on postprandial TG
lowering in both C57BL=6J mice and ASP deficient mice and
delayed TG clearance in ASP deficient (C3 knockout).30 – 32
There is already a long list of factors which have been
demonstrated to modulate food intake when administered
peripherally. They include members of the gastrointestinal
hormone family (CCK, bombesin, gastrin releasing peptide,
glucagon-like peptide-1 as well as others), pancreatic poly-
peptides (insulin, glucagon, peptide YY) as well as other
circulating factors (leptin, opioids).3 Despite evidence that
administration of these peptides influences feeding beha-
viour, it is still unclear whether many of these peptides act
via a central or peripheral mechanism. The data presented
here suggest that ASP increases food intake acutely, but that
food intake equilibrates overall within a 24 h period. This is a
similar pattern to CCK where acute administration inhibits
food intake in the short-term, however repeated injections
result in smaller but more frequent meals without a change
in total daily caloric input and body weight.1,2 The time
course of the effect also suggests that ASP is acting periph-
erally but not centrally, since a more rapid response is
observed when ASP is administered i.p. By contrast, leptin
action is much more potent when administered centrally
than peripherally.10
ASP appears to attenuate the increase in glucose seen after
a meal in db=db and ob=ob mice (as presented here) and also
in B6 control mice.30 Campfield et al have demonstrated that
small transient decreases in glucose precede spontaneous
meal intake and blocking these decreases can prevent meal
initiation.1,2 Thus the effect of ASP administration is consis-
tent with a short-term increase in food intake induced by
small (10%) decreases in plasma glucose levels and follows a
similar temporal profile to the changes in plasma glucose (B6
control mice30 and ob=ob mice). In the db=db mice, glucose
levels are markedly increased due to increased hepatic glu-
coneogenesis which is further stimulated by the fatty acid
intake50 – 52 and ASP has less of an effect.
This acute effect of ASP (on food intake) would appear to
contrast with ASP deficient (C3 knockout) mice which have
slightly increased food intake.32 They also manifest reduced
adipose tissue mass but normal fat absorption.34 On the
surface, these two effects might appear to be contradictory.
However, both effects on food intake are probably indirect,
and can be explained more clearly by examining the direct
ASP target: dietary substrate utilization. Thus in the first
instance, with increased ASP, an ASP effect on tissue fatty
acid and glucose uptake reduces circulating glucose and
increases food intake. In the ASP deficient mice, a lack of
ASP reduces dietary fat storage, adipose tissue mass decreases,
plasma leptin decreases, plasma insulin is lower and the mice
consequently eat more to re-establish metabolic balance and
adipose tissue mass. Thus the different effects on food intake
Figure 5 Postprandial human ASP in ob=ob and db=db mice. ob=ob
and db=db mice (as described in Figures 1 and 2) were injected i.p. with
ASP at time 0 in eight ob=ob (C57BL=6J-Lepob) and nine db=db
(C57BLKS=J-Leprdb) mice. Human ASP levels in the mouse plasma were
then measured serially postprandially as shown (average s.e.m.).
Figure 6 Postprandial glucose in ob=ob and db=db mice. A fat load was
administered at time zero with or without i.p. injection of ASP (as
indicated). Plasma glucose was then measured serially. Results are pre-
sented as average s.e.m. for eight ob=ob and nine db=db mice. Results
were analyzed by RM ANOVA with Bonferroni post-hoc test for differ-
ences at specific time points with vs without ASP where: ob=ob, P<0.05
time, P0.009 group; db=db P<0.0001 time, P NS group and
*P<0.05 for individual time points with vs without ASP.
ASP in ob=ob and db=db mice
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are indirect and mediated through different metabolic
effects.
In db=db mice, plasma TG and cholesterol increase early in
development and are not simply secondary to the obesity
which develops.53 Studies by Li et al have demonstrated that
the increase in plasma TG is not due to increased hepatic
lipogenesis or apolipoprotein B secretion, but decreased
plasma TG clearance.54 This might be explained by a
decrease in LPL activity, but there is no published data on
adipose tissue or muscle LPL or postprandial TG lipemia in
db=db mice. Nonetheless, as there are many published
reports of disordered glucose metabolism and insulin resis-
tance in db=db mice, presumably this would apply to the
insulin-mediated stimulation of LPL mass and activity
as well.
One of the features of the ASP induced drop in postpran-
dial lipemia in this study is that the magnitude of the ASP
effect is proportional to the postprandial lipemia. Thus,
those animals which demonstrate the greatest postprandial
lipemia; db=db mice and ASP-deficient (C3 knockout)
mice31,32 also demonstrated the greatest response to i.p.
ASP. On the other hand, in those mice with moderate
postprandial lipemia such as ob=ob and B6 control mice,30
the overall effect of ASP was moderate. Although we have
not measured murine ASP directly in these mice, there is
evidence that adipsin, an adipocyte specific enzyme, is
markedly reduced in db=db mice.55 As adipsin is obligatory
to generating ASP via the alternate complement pathway
interaction of C3, factor B and adipsin, ASP levels might be
expected to be low as well. Thus, in the db=db mice, and ASP-
deficient (C3 knockout) mice the potent effect of adminis-
tered ASP may be a result of low or no endogenous murine
ASP.
What is the potential mechanism of action of ASP, espe-
cially in the db=db mice which have such a proportionally
greater response to ASP? First, ASP increases intracellular
esterification (and thus uptake) of NEFA, as shown in cul-
tured adipocytes.4,21 Secondly, ASP may enhance TG clear-
ance by preventing NEFA inhibition of LPL through its tissue
NEFA sequestration action. Both in vitro and in vivo studies
have demonstrated an inhibitory and destabilizing effect of
NEFA on LPL.56 – 60 Finally, ASP also reduces plasma NEFA
through inhibition of adipocyte hormone sensitive lipase.23
All of these mechanisms may contribute to the ASP post-
prandial effect. In this study we chose to use a fat load rather
than a mixed meal in order to avoid insulin changes post-
prandially so that the changes would reflect primarily an ASP
effect. As ASP and insulin effects are additive in vitro21,23,24,28
the interplay between the two will need to be examined in
vivo in the future.
Endogenously leptin, insulin, glucocorticoids and ASP
appear to provide a coordinated balance=counterbalance on
energy intake centrally and energy storage peripherally. Thus
insulin reduces energy intake, but increases energy storage,
while glucocorticoids have opposite effects to those of
insulin. On the other hand, leptin inhibits both food
intake and the storage of lipid in adipose tissue, whereas
ASP stimulates both processes. Thus the ASP system may
provide a pharmacologic target to alter adipocyte and lipid
metabolism.
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